Complete Response in Recurrent End-Stage Pancreatic Cancer After Combined Immune Cell Therapy of α-Galactosylceramide Dendritic Cell Vaccine Therapy, Wilms' Tumor 1 Dendritic Cell Vaccine and Natural Killer Cell Therapy. [PDF]
Liu K, Nagai H, Kanai N, Yamahara K.
europepmc +1 more source
Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide. [PDF]
Romanò C +14 more
europepmc +1 more source
Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer. [PDF]
Wang Y, Bhave MS, Yagita H, Cardell SL.
europepmc +1 more source
Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs. [PDF]
Artiaga BL +13 more
europepmc +1 more source
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. [PDF]
Toyoda T +12 more
europepmc +1 more source
Combination of Radiation Therapy, Wim's Tumor 1 (WT1) Dendritic Cell Vaccine Therapy, and α-Galactosylceramide-Pulsed Dendritic Cell Vaccine Therapy for End-Stage Small Bowel Cancer. [PDF]
Nagai H +5 more
europepmc +1 more source
Bacterial immunogenic α-galactosylceramide identified in the murine large intestine: dependency on diet and inflammation. [PDF]
von Gerichten J +13 more
europepmc +1 more source

